KAKEN PHARMACEUTICAL CO.,LTD. (4521.T) Financial Statements

Income statement

Metric	TTM	2026	2025	2024	2023
Revenue
Total Revenue	76.9B	76.9B	94.0B	72.0B	73.0B
Cost of Revenue	9.0B	36.9B	35.5B	33.5B	33.4B
Gross Profit	9.9B	40.0B	58.5B	38.5B	39.6B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	9.9B	40.9B	37.5B	29.0B	31.6B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	9.9B	40.9B	37.5B	29.0B	31.6B
Cost and Expenses	77.8B	77.8B	73.0B	62.5B	65.0B
Operating Income (EBIT)	(899.0M)	(899.0M)	21.0B	9.5B	8.0B
Non-Operating
Interest Income	43.0M	275.0M	77.0M	8.0M	7.0M
Interest Expense	10.0M	45.0M	28.0M	17.0M	17.0M
Net Interest Income	33.0M	230.0M	49.0M	(9.0M)	(10.0M)
Other Non-Op Income/Expense	404.0M	693.0M	245.0M	437.0M	729.0M
Non-Operating Income (excl Interest)	385.0M	691.0M	624.0M	535.0M	773.0M
EBT (Pre-Tax Income)	409.0M	2.3B	19.4B	9.8B	6.8B
Income Tax Expense	137.0M	168.0M	5.5B	1.8B	1.4B
Bottom Line
Net Income	2.1B	2.1B	13.9B	8.0B	5.4B
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	2.1B	2.1B	13.9B	8.0B	5.4B
Per Share
Basic EPS	¥57	¥57	¥365	¥213	¥145
Diluted EPS	¥57	¥57	—	—	—
Revenue Per Share	¥2,028	¥2,028	¥2,464	¥1,909	¥1,943
Shares
Basic Shares Outstanding	37.9M	37.9M	38.2M	37.7M	37.6M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	—	2.2B	23.5B	12.1B	10.5B
D&A	—	3.1B	2.5B	2.6B	2.5B
EBIT	(899.0M)	(899.0M)	21.0B	9.5B	8.0B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026